Recent Updates
Recently added Catalysts
IVVD Positive Sentiment Score: 75/100

Invivyd to Participate in Upcoming Investor Conferences

Key Takeaway: Invivyd, Inc. announced its participation in two upcoming investor conferences: the Guggenheim 5th Annual Inflammation, Neurology & Immunology Conference on November 7, 2023, and the Evercore ISI 6th Annual HealthCONx Conference on November 30, 2023. The company aims to deliver antibody-based therapies to protect vulnerable populations from viral infectious diseases, beginning with COVID-19. They utilize advanced technology combining evolutionary virology and antibody engineering to develop their therapeutic pipeline.

Market Sentiment Analysis

POSITIVE FACTORS

  • Invivyd is participating in notable investor conferences, highlighting its engagement with the investment community.
  • The company's focus on antibody-based therapies could address significant public health needs, potentially improving their market position.
  • They have a robust pipeline targeting multiple viral diseases, which showcases innovation and growth potential.

Full Press Release Details

WALTHAM, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, today announced that it will present at the following investor conferences:
Guggenheim 5th Annual Inflammation, Neurology & Immunology (INI) Conference
Fireside Chat Date: Tuesday, November 7, 2023
Fireside Chat Time: 3:50 PM ET
Location: New York, NY
Evercore ISI 6th Annual HealthCONx Conference
Fireside Chat Date: Thursday, November 30, 2023
Fireside Chat Time: 10:50 AM ET
Live webcasts of the fireside chats will be available in the investor section of the company's website at investors.invivyd.com and will be archived for approximately 30 days following the events.
Invivyd, Inc. (Nasdaq: IVVD) is a biopharmaceutical company on a mission to rapidly and perpetually deliver antibody-based therapies that protect vulnerable people from the devastating consequences of circulating viral threats, beginning with SARS-CoV-2. ​​Invivyd’s technology works at the intersection of evolutionary virology, predictive modeling, and antibody engineering, and is designed to identify high-quality, long-lasting antibodies with the potential to resist viral escape. The company is generating a robust pipeline of product candidates which could be used in prevention or treatment of serious viral diseases, starting with COVID-19 and expanding into influenza and other high-need indications. Visit https://invivyd.com/ to learn more.
Gabriella Linville-Engler

Frequently Asked Questions

When will Invivyd present at the Guggenheim Conference?

Invivyd will present on November 7, 2023, at 3:50 PM ET.

Where can I watch Invivyd's fireside chats?

Live webcasts will be available on Invivyd's investor section for 30 days.

What is Invivyd's mission?

Invivyd aims to protect vulnerable individuals from serious viral diseases.

What therapies does Invivyd focus on developing?

Invivyd specializes in antibody-based therapies for viral infections like COVID-19.

What types of diseases is Invivyd targeting?

Invivyd focuses on viral diseases including COVID-19 and influenza.

Last updated: Oct 31, 2023